Furthermore, LYPD3 has been demonstrated to be highly expressed in several human malignancies, such as breast cancer, colorectal cancer, esophageal cancer, renal cell carcinomas, and so forth (Fletcher et al., 2003; Hansen et al., 2004; Hansen et al., 2008; Miyake et al., 2015; Cohen et al., 2017; Hu et al., 2020; Monteiro et al., 2020). Here, LYPD3 is linked to breast carcinoma.